



CUBE LABS[®]

CORPORATE PRESENTATION

DISCLAIMER

CONFIDENTIALITY

This Document has been drafted by Cube Labs S.p.A. (hereinafter the "Company") solely for the purpose of this presentation. The Document may not be reproduced or distributed, in whole or in part, by any person other than the Company. The Company assumes no responsibility for the use of this document by any person and for any purpose whatsoever.

INFORMATION

The Document does not represent in its entirety either the Company or the project it intends to implement and, therefore, some information inherent to it may have been omitted. Cube Labs, in any case, specifies that the information represents a summary of the company's information assets, which is necessary for the purposes of this Corporate Presentation, and therefore does not guarantee the exhaustiveness of the information provided nor its continuous updating.

GENERAL CONDITIONS

Although care and diligence has been taken in the preparation of the Document, the Company makes no representations or warranties, express or implied, as to the completeness, accuracy, or correctness of the information, forecasts, or opinions expressed therein. Some parts of the Document contain statements with long-range forecasts, which represent estimates that are subject to risks or uncertainties and which, therefore, could differ, even substantially, from future results.

CUBE LABS®

Cube Labs SpA

Legal Seat: Rome, 00198 via Giulio Caccini, 1

Phone: +39 06 855 7752 | e-mail: info@cube-labs.com

FOUNDERS



Filippo Surace
Founder & CEO

EDUCATION AND TRAINING



KEY PROFESSIONAL EXPERIENCE



Renato Del Grosso
Co-Founder &
Chief Strategy Officer

EDUCATION AND TRAINING



UNIVERSITÀ DEGLI STUDI DI NAPOLI
FEDERICO II

KEY PROFESSIONAL EXPERIENCE



Massimo Focchi
Co-Founder &
Chief Financial Officer

EDUCATION AND TRAINING



Università
Bocconi
MILANO

KEY PROFESSIONAL EXPERIENCE




DI TANNO ASSOCIATI




INDEX

1	COMPANY OVERVIEW	p. 5
2	BUSINESS MODEL	p. 13
3	SPIN-OFF PORTFOLIO	p. 18
4	IPO	p. 25
5	CAPITAL INCREASE	p. 30
6	FINANCIAL RESULTS	p. 32
7	ESG IMPACT	p. 35
8	APPENDIX: TEAM AND STRATEGIC ADVISORY BOARD	p. 38



1 COMPANY OVERVIEW



CUBE LABS AT A GLANCE

CUBE LABS®


Cube Labs S.p.A. is an Italian Venture Builder specialized in the development of projects in the healthcare technologies sector. Cube Labs has been **listed** since March 21, 2023 on **Euronext Growth Milan** - Professional segment, dedicated to SMEs with high growth potential.




3 offices (Milan, Rome, Lecce) and a team with deep expertise in healthcare industry.



Shares in 18 companies, with a value of € 56.1 million¹.



Network of international partners and exclusive partnership with the Biostructures and Biosystems National Institute (INBB).



Strategic Advisory Board composed of 12 key people with international expertise.

1. As of 31 December 2025.

OUR FIGURES

18

Spin-offs¹

56.1M€

Assets
value³

9

Exclusive
licenses

24

Universities
in INBB
network¹

60

patents

88

Research
centers in CNR
network²

700

Researchers in
INBB network¹

1. www.inbb.it/chi-siamo/universita-aderenti.

2. www.cnr.it/en/cnr-in-figures.

3. As of 31 December 2025.

GOVERNANCE AND SHAREHOLDING

BOARD OF DIRECTORS

Filippo Surace
Chairman and CEO

Renato Del Grosso
Member of Board

Massimo Fiocchi
Member of Board

Domenico Colella
Non-executive Director

Giuseppina Staropoli
Independent Director

AUDITING FIRM



Grant Thornton

BOARD OF STATUTORY AUDITORS


Piergiacomo Jucci
President of the Board of Auditors

Marco Ziccardi
Standing Statutory Auditor

Alessandro De Luca
Standing Statutory Auditor

Fabrizio Iacuitto
Alternative Statutory Auditor

Alessandro Medici
Alternative Statutory Auditor



** of which **7.69%** is held by **Algebris Investment Ltd.**

* The shareholding of Filippo Surace is 60.50%, of which 51.56% is held through Keltinvest S.r.l., a company that Surace himself controls 100% and of which he is sole director, and the remaining 8.94% directly as a physical person.

DEVELOPMENT STRATEGY

SHORT TERM STRATEGY

VALORIZATION OF THE SUBSIDIARY COMPANIES BY INCREASING R&D ACTIVITY ON SELECTED INITIATIVES

Cube Labs intends to increase its R&D activity in order to advance the development of selected portfolio technologies. The aim of the Society is to ramp up research lines, towards:

- Phase 1-2 in the biopharma field;
- TRL 8-9 in the MedTech sector;
- Market access for nutraceutical products.

ADVISORY ACTIVITY INCREASE

As a Venture Builder, Cube Labs aims to increase strategic, operational and financial consulting to selected companies through IPO fundraising.

MID-LONG TERM STRATEGY

R&D ACTIVITIES ON ADDITIONAL INITIATIVES ALREADY IN THE PORTFOLIO

CORPORATE FINANCE & COMMERCIAL OPERATIONS

Cube Labs intends to enhance the value of its holdings through extraordinary transactions:

- Outlicensing of single asset;
- M&A;
- IPO.

INCREASE OF SUBSIDIARY COMPANIES IN PORTFOLIO

Thanks to the exclusive partnership with Modi Science Foundation and its network, Cube Labs intends to continue founding new companies through next rounds of fundraising.



OUR STORY

2013

Cube Labs Incorporation

CUBE LABS®

2014 - 2016

- Pilot program and scientific networking;
- *Blue ocean* expansion in China, Spain and CEE.

CHINA AWARDS
2014

2017 - 2020

- 10 new portfolio companies in partnership with I.N.B.B.;
- Expansion in Switzerland and Israel;
- Seed investment by CDP VC SGR in 4 spin-offs.

LE FONTI AWARDS
WINNER 2018

cdp
CDP Venture Capital Sgr

2021 - 2022

- Agreement for a 7,2M€ Co-investment in the portfolio with CDP VG SGR;
- **Pre-IPO Launch.**

LE FONTI AWARDS
WINNER 2021

LE FONTI AWARDS
WINNER 2022



2023

EGM professional segment quotation.

- **IPO Market Cap 34,105M€:**
Title performance +6,5% up to December 2023;
- Market Cap 36,865M€.

EURONEXT
IPO 2023

PRIX GALIEN USA
2023 SHORTLIST

LE FONTI AWARDS
WINNER 2023

POLITECNICO
MILANO 1863
SCHOOL OF MANAGEMENT
TOP EXIT 2023

2024

Global scale-up.

- Strategic partnerships in India and the UAE;
- Completed a capital raising of **2,658,370€.**

Flagship Partner of
PRIX GALIEN
INTERNATIONAL
2024

PRIX GALIEN USA
2024 SHORTLIST

2025


- 2 new portfolio companies.

efi
2025
CHAMPION OF
SCALABLE
MARKET-READY
HEALTHCARE
VENTURES
WINNER ITALY

Premio categoria
"INNOVAZIONE"
MOTORE
ITALIA
P.R.I.V.A.

PREMIUM AWARD
2025
CHINA
AWARDS
2003 - 2021

GLOBAL FOOTPRINT



Italy



France



Poland



Spain



Germany



UNIVERSITÀ
DEL SALENTO

Italy



National Research
Council of Italy

Italy



USA



Israel



India

ACCELERATING ESG IMPACT



DEMOCRATIZATION

Pervasive knowledge as a widespread economic advantage. The **technology transfer** through the academic research brings technological solutions into everyday life.



ACCESSIBILITY


Life Sciences **accessible to all**. Our vision, our tangible commitment. So that **no community or individual is left behind**.



A HEALTHIER FUTURE

Our **ESG approach** for a healthier future. Promoting innovation and supporting the spin-off ecosystem in alignment with the United Nations' **2030 Agenda for Sustainable Development Goals**.


BUSINESS 2 MODEL



OUR VENTURE BUILDING APPROACH

Cube Labs builds new companies from promising R&D activities, transforming pioneering science into real-world healthcare solutions. As a venture builder, it supports selected projects from their earliest stages:

BUILDING



We source proprietary science to build promising healthcare technology companies from scratch.

FINANCING



We provide funding to drive innovation.

GROWTH



We provide entrepreneurial and operational support to develop healthcare technologies for the global market.

BUSINESS MODEL

Cube Labs is a shareholder of subsidiaries that hold academic research projects that have passed the Proof of Concept (PoC), and that come mainly from the partnership with INBB.

The Company selects academic projects with high development potential.

A key point of Cube Labs' business model is the corporate and organizational control of the investees, according to the typical Venture Builder model.

The business model of Cube Labs is to take equity participations, also jointly with other partners, in pre-seed/seed-round. The shareholding of each of the investees will be divided into three components:

CUBE LABS

BUSINESS COMPONENT

Cube Labs intervenes with a **majority stake** in the companies and, currently, in special Trust of which CL will be the sole beneficiary with a **minority stake**.

RESEARCHERS

SCIENTIFIC COMPONENT

Researchers (sponsors of academic spin-off) hold a **minority share** of subsidiary company.

INBB

ACADEMIC COMPONENT

INBB holds a minority share.

KEY SUCCESS FACTORS



FIRST MOVER

Cube Labs is the first venture builder in healthcare sector, listed on EGM – Professional segment.



SUCCESSFUL TEAM

Experts with international experience in both industry-leading companies and top academic and scientific institutions.



HIGH DEGREE OF CONTROL

From the initial stages to the commercialization of the technology.



STRATEGIC PARTNERSHIP WITH INBB

Cube Labs has a preferential access to Italian academic excellence (right of priority through right of first refusal agreement).



INTERNATIONAL NETWORK

Developed through strategic partnerships with leading national and international institutions.



GROWTH TREND IN THE SECTOR

National and European investments to support Academia and Life Science research.


REVENUE MODEL

Innovative revenues model with streamline from spin-offs to the Holding enabling Cube Labs to be independent from continuous capital injections in order to improve its spin-offs portfolio up to the exits.

Service Fee	E.G. co-working spaces, international desks, facilities, advisory, mentoring	Monthly Fee
Royalty Fee	Commercial deals with global stakeholders	% of Spin-off licensing revenue from spin-offs
Fundraising Fee	Fundraising on the private capital market	% of the funds allocated
Exit Fee	Advisory services in exit phase	% of exit value



3 SPIN-OFF PORTFOLIO



OUR FOCUS AREAS



PHARMACEUTICALS

Preclinical or phase 1 clinical phase.



BIOTECH

Between TRL 3 and TRL 7.



NUTRACEUTICALS

Synthesis phase of active substance achieved or clinical validation achieved.



R&D TECH/AI

Artificial Intelligence applied to bio-health sector.




MEDTECH

Between TRL 3 and TRL 7.

AI AS A TRANSLATIONAL ACCELERATOR

By embedding AI across MedTech and Drug Development, Cube Labs advances innovation, optimizes pre-clinical pathways, and strengthens translational impact.



SPIN-OFF PORTFOLIO

PHARMACEUTICALS



Regenerative technologies against osteoarthritis and related diseases. They developed a molecule that stimulates the formation of new cartilage tissue.

Shareholding

Cube Labs	51%
Trust Cube Labs	12%
INBB	5%
Scandurra	32%

Funded by CDP - Italian Capital

PHARMACEUTICALS



LA TECNOLOGIA CONTRO LE MALATTIE ORFANE

Solutions for the treatment of rare diseases, which occur rarely and for which there are currently no therapies (e. g. autoimmune diseases such as systemic sclerosis).

Shareholding

Cube Labs	51%
Trust Cube Labs	44%
INBB	5%

Funded by CDP - Italian Capital

PHARMACEUTICALS



Development of natural and synthetic molecules for diabetes, obesity control, and liver health, with nutraceutical and pharmacological applications.

Shareholding

Cube Labs	60%
Falasca	35%
INBB	5%

PHARMACEUTICALS



Research and development of therapeutic molecules, with particular attention to those used in the treatment of diabetic neuropathy and Alzheimer's.

Shareholding

Cube Labs	51%
Trust Cube Labs	14%
INBB	5%
Pappalardo	30%

Funded by CDP - Italian Capital

NUTRACEUTICALS/MEDTECH



Innovative Alzheimer's diagnostic method for early intervention. Neuroprotective saffron-based supplement targeting oxidative stress and inflammation in neurodegenerative conditions.

Shareholding

Cube Labs	51%
Trust Cube Labs	9%
INBB	5%
Hortus Novus	35%

Funded by CDP - Italian Capital

NUTRACEUTICALS



Development of bioactive Molecules derived from green tea catechins with anti-oxidant and anti-inflammatory effects. Applications: LUTS, IBS, Wound Care, and Sports Medicine.

Shareholding

Cube Labs	51%
Trust Cube Labs	4%
INBB	5%
Morini	16%
Bettuzzi	24%

SPIN-OFF PORTFOLIO

NUTRACEUTICALS



Myrtoviva aims to innovate the field of food supplements and cosmetic products by the combination of traditional Mediterranean phytoextracts and the use of nanotechnology.

Shareholding

Cube Labs	65%
INBB	5%
Maioli	30%

COSMETICS



Pioneering dual-component technology combining a biocompatible carrier and microbiome-based formulation to aid wound recovery and optimize scar appearance.

Shareholding

Cube Labs	65%
INBB	5%
Papa	10%
Lozio	10%
Colussi	10%

R&D TECH/AI



Development of Artificial Intelligence applications for the bio-health/ healthcare sector.

Shareholding

Cube Labs	51%
Trust Cube Labs	9%
Tracanna	40%

MEDTECH



Technologies for the improvement of absorbent products (e. g. diapers), aiming to reduce environmental impact, through a patented process.

Shareholding

Cube Labs	50.4%
Trust Cube Labs	34%
INBB	5%
Chiarelli	5%
Albanese	5%
Others	0.6%

MEDTECH



A spray-on bandage capable of detecting the early signs of bacterial infections through a color change. An innovative approach to the treatment of superficial wounds.

Shareholding**

Cube Labs	95%
INBB	5%

MEDTECH



Development of technologies for endovascular robotics.

Shareholding

Cube Labs	55%
INBB	5%
G. Danieli	40%

* The date of Company's incorporation.

** By September 30, 2025, 35% of Cube Labs' shareholding will be allocated to the inventor shareholders as formal recognition of the know-how and technical-scientific contributions they have provided.

SPIN-OFF PORTFOLIO

MEDTECH



Biocompatible, biodegradable, and in situ cross-linkable hydrogels that adhere to both soft and hard tissues, enabling controlled, localized release of active medicinal substances for enhanced bio-availability.

Shareholding

Cube Labs	51%
Trust Cube Labs	9%
INBB	5%
Chiarelli	35%

MEDTECH



Advanced technologies for detecting micro- and nanoplastics. Using electronic devices with fluorogenic probes, it identifies microplastics of various sizes and characteristics in fluids.

Shareholding

Cube Labs	55%
Genovese	10%
Prodi	10%
Rampazzo	10%
Zaccheroni	10%
INBB	5%

MEDTECH



Development of bio-sensors for diagnostic, veterinary, environmental and agri-food analytical tests.

Shareholding

Cube Labs	51%
Trust Cube Labs	4%
INBB	5%
Roda	40%

MEDTECH



Technologies to improve visibility during cardiac procedures and development of protocols and technologies for the treatment of refractory infarction.

Shareholding

Cube Labs	51%
Trust Cube Labs	9%
INBB	5%
S. Massetti	35%

MEDTECH



Innovative thermo-graphic imaging embedded in a bandage for non-invasive vascular assessment. Enhancing patient monitoring and optimizing clinical outcomes.

Shareholding

Cube Labs	51%
Trust Cube Labs	4%
INBB	5%
Papa	10%
Radio Analog	
Micro Electronics	30%

ACCELERATOR




Company that supports start-ups in business development by providing professional services (strategy definition, market analysis, mentorship, etc.).

Shareholding

Cube Labs	14.4%
G2 Startup S.r.l.	25%
Others	60.6%

FULL ASSET VALUATION: OVERVIEW

This overview facilitates direct comparison, **highlighting the increased portfolio value (M€) due to recent developments.**




* Valuation performed in October 2022.

** Valuation performed in October 2025.

These valuations were performed by **Venture Valuation AG**, an independent Swiss company with 20+ years expertise in the life sciences industry.

4 IPO



LISTING IPO EGM PRO

Number of shares pre-IPO	15,000,000
Shares newly issued	5,879,010
Number of outstanding shares	20,879,010
Free Float	28.79%*
IPO Date	March 21, 2023
Issue Price (€)	2.00
Market Cap (€/M) @ IPO	34,105
Market	EGM PRO
Title update since IPO to 12/05/2026	+23%
Title update YoY to 12/05/2026	+9.2%
Last price to 12/05/2026 (€)	2.46
Market Cap to 12/05/2026 (€/M)	51,362**



EGM

As of December 31, 2025, the EGM counted 213 companies with a total market capitalization of 10.2M€.

In 2025, 22 companies went public through IPOs, raising a total of EUR 126.2 million.

Source: Borsa Italiana

* of which **7.69%** is held by **Algebris Investment Ltd.**

** The **Market Cap** includes the latest capital increase subscription on November 27, 2025.


EGM PRO PERFORMANCE

Price per Share at IPO: 2€
[IPO March 2023]




EGM PRO BENCHMARK

NAME	SYMBOL	INDUSTRY	PRICE	MTD	YTD	YOY	MARKET CAP (M€)
ABC Company	ABC.MI	Industrials	4.00	0.00%	6.38%	8.11%	65.97
Acquazzurra	ACQ.MI	Advertising Agency	10.50	0.00%	0.00%	0.00%	27.13
BolognaFiere	BF.MI	Consumer Discretionary	1.25	0.00%	0.00%	0.00%	243.5
Cogefeed	CGF.MI	Energy	1.10	0.00%	20.88%	57.14%	5.66
Creatives Group	CREG.MI	Software Application	2.96	0.00%	15.63%	9.63%	43.76
Cube Labs	CUBE.MI	Financials	2.46	0.00%	1.65%	9.82%	50.2
Dotstay	DOT.MI	Real Estate	2.08	4.00%	12.43%	15.56%	8.44
e-Novia	E9IA.MI	Financials	2.00	0.00%	0.00%	-8.26%	70.77
Egomnia	EGN.MI	Industrials	-	0.00%	0.00%	0.00%	-
gAln360	GAIN.MI	Software Application	1.56	0.00%	-5.96%	0.00%	9.56
Homizy	HZY.MI	Real Estate	3.88	0.00%	0.00%	0.00%	39.55
Praexidia	PRXD.MI	Industrials	-	0.00%	0.00%	0.00%	-
Smart Capital	SMCAP.MI	Financials	1.55	0.00%	-1.27%	0.00%	53.13
Yakkyo	YKY.MI	Industrials	1.36	-2.86%	36.00%	36.00%	7.47



COMPANY PORTFOLIO VALUE BREAKDOWN

ESTIMATED PORTFOLIO OF INVESTEE COMPANIES



Intermonte, independent corporate broker, identifies **significant growth** potential for the company.

NAV

The dynamic **NAV per share is projected to be €4.3** per share.


In future years, while various project milestones are achieved, the potential **NAV** will reach the amount of **€86.7 million** (vs €77.6 million at initiation of coverage).

Long-term projections (2030+) suggest a **NAV of €450 million** (vs €390 million at initiation of coverage), about 10x the current market capitalization.

VALUE PER SHARE

BUY rating and a target price of **€3.25** per share, with a **potential upside of +37%**.

5 CAPITAL INCREASE



CAPITAL INCREASE

Up to € 15,000,000.00

The Extraordinary Shareholders' Meeting of Cube Labs S.p.A. approved the delegation to the Board of Directors to increase the share capital, for consideration, **in one or more tranches and on a divisible or indivisible basis**, for a maximum total amount of €15 million, including any share premium.

The Board of Directors will determine, from time to time, the number of shares to be issued, the issue price and the other terms and conditions of each transaction, in compliance with applicable laws and regulations.



The Capital Increase will have the requirement of **divisibility** (i.e., it may be subscribed in installments).




The capital increase may be carried out through the issuance of new shares, also with the option to exclude pre-emption rights and with the possibility of issuing non-voting shares.



The Capital Increase is to be carried out **no later than May 26, 2031**.

This capital increase is intended to provide Cube Labs with flexibility and speed of execution to access new financial resources, support working capital, fund the development plans of its subsidiaries and portfolio companies, and seize strategic business or growth opportunities.

6 FINANCIAL RESULTS



BALANCE SHEET

Balance sheet (€/000)	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Intangible asset	10	9	15	344	1,161	1,039	807
Tangible asset	2	2	3	2	1	6	6
Financial asset	349	51,744	52,108	52,312	53,104	53,736	56,087
Assets	361	51,755	52,126	52,657	54,266	54,781	56,900
Other non-current assets	-	-	-	53	128	112	105
Net working capital	1,631	2,402	2,122	3,352	4,883	6,134	8,127
Reserves	(9)	(11)	(13)	(12)	(4)	(21)	(28)
Invested capital	1,983	54,146	54,235	56,051	59,273	61,006	65,104
Equity	1,369	53,020	52,267	52,460	57,444	59,356	62,393
NFP	593	1,057	1,771	3,272	1,569	1,650	2,647
Adjusted NFP*	614	1,126	1,968	3,591	1,829	1,701	2,711
Sources	1,983	54,146	54,235	56,051	59,273	61,006	65,104

* In the adjusted NFP, overdue tax payables are included, but trade payables overdue by more than 60 days are not considered, leaving them reclassified in the NWC, as they are regularly paid in the short term.

BALANCE SHEET - NOTES

Net Financial Position as of December 31, 2025, stood at negative € 2.6 million, compared to negative € 1.7 million as of December 31, 2024, and negative € 2.8 million as of June 30, 2025. As of year-end 2025, Cube Labs reported cash and cash equivalents of € 1.1 million, broadly in line with the € 1.2 million reported at the end of the previous financial year.

Among the components of the Net Working Capital, trade receivables stand out, which include reclassified receivables from customers and receivables from subsidiaries and associates due to the company's specific business model. These receivables are not overdue as they consist of invoices to be issued for €8.4 million.

INCOME STATEMENT


Income statement (€/000)	FY 2020	FY 2021	FY 2022	FY2023	FY 2024	FY 2025
Value of production	950	1,127	1,143	1,637	2,108	2,910
Var YoY%	+67.3%	+18.6%	+1.42%	+43.2%	+28,8%	+38%
Raw materials	(2)	(5)	(3)	(3)	(5)	(6)
Services	(410)	(571)	(903)	(1,745)	(1,895)	(1,562)
Rent and leasing	(27)	(36)	(65)	(108)	(151)	(154)
Personnel cost	(74)	(64)	(90)	(142)	(449)	(534)
Other	(10)	(39)	(28)	(62)	(77)	(68)
EBITDA	426	412	54	(423)	(469)	586
EBIT	332	406	48	(649)	(803)	232
EBT	309	335	(91)	(916)	(986)	12
Net income	220	215	(73)	(695)	(730)	7

INCOME STATEMENT - NOTES

Revenue from core operations totaled €2.8 million, compared to €2.0 million in 2024. The vast majority of the Company's revenue is generated through consulting and support services provided to portfolio companies. The year-on-year increase mainly reflects the higher level of services delivered under existing service agreements in support of the development and acceleration initiatives undertaken by portfolio companies, together with the continued expansion of the Company's investment portfolio.

EBITDA amounted to €586 thousand, compared to a negative EBITDA of €469 thousand in FY2024, benefiting from lower service costs, which decreased from €2.0 million in 2024 to €1.7 million in 2025. After net financial expenses of €219 thousand, compared to €182 thousand in FY2024, and income taxes of €5 thousand, Net Profit amounted to €7 thousand, compared to a net loss of €731 thousand in the previous year.

7 ESG IMPACT



DEMOCRATIZATION OF LIFE SCIENCES: THE 5 A's

Affordability

The extent to which a patient's financial ability matches the cost of the service and/or care.

Availability

The availability of necessary resources such as personnel, technology, and care to meet the patient's needs.

Accessibility

How easily the patient can physically access the location of the service.

Accommodation

The degree to which services (working hours, availability, ease of communication, etc.) respond to the patient's needs.

Acceptability

The level of comfort the patient feels with the unchangeable characteristics of the service/care (e.g., age, gender, social class, ethnicity, diagnosis, beliefs).

DEMOCRATIZATION: THE VENTURE BUILDER'S ROLE

BRIDGING THE GAP BETWEEN SCIENCE AND MARKET

Advancing scientific discoveries to market through partnerships, faster development, and **improved accessibility**.

COST CONTAINMENT STRATEGIES

Reducing healthcare costs through **investments in preventive care, digital health technologies, and personalized medicine**.

ETHICAL FUNDING SOURCES

Partnering with investors who share our values, while **staying true to our mission**.


R&D EXPENSES

Focusing on recovering and enhancing university-driven R&D, **maximizing both impact and return on investment**.

BALANCING PRIMARY VS. EMERGING MARKETS

While primary markets offer quicker financial returns, **innovative healthcare solutions in emerging markets can have a greater impact**.

8 APPENDIX: TEAM AND SAB



BOARD OF DIRECTORS



Filippo Surace
Chairman & CEO

- Serial entrepreneur and innovator with 30+ years of experience in the medical field with extensive expertise in leading healthcare organizations and strategic investments.
- Founder & Chief Executive Officer of Gruppo Surace and of Cube Labs S.p.A.
- Former President of the Pharmaceutical and Healthcare Division of Confindustria Lecce.
- Associate Professor at Temple University Center for Biotechnology College of Science and Technology, Philadelphia US.



Renato Del Grosso
Chief Strategy Officer

- 17+ years' experience in market access and government affairs acquired in several large corporations in the pharmaceutical and medical fields (MSD, Abbott Diagnostics, Abbvie, and Intercept Pharmaceuticals).
- Mentored academic spin offs directly and via accelerators in Italy, Switzerland, UK, Poland, Finland, Norway, and Austria. He is Chief Strategy Officer and Board Director at Cube Labs.
- Angel investor and life sciences expert.



Massimo Fiocchi
Chief Financial Officer

- Certified accountant with extensive experience working with both local and international companies across various sectors, including banking and finance.
- Served as advisor to Bank Foundations and Non-Profit Organizations and Founder of Fiocchi Tirrito, a law and tax firm in Rome.
- Former board director and board member of statutory auditors for limited liability and joint-stock companies, and external auditor for public bodies and liquidator for special purpose entities in securitization transactions.



Domenico Colella
Non-executive Director

- He has been a consultant for Banca Cattolica S.p.A., an Associate Lawyer at Baker & McKenzie in Rome,
- Co-founded Portolano Colella Cavallo law firm in 2001, focusing on intellectual property and technology law.
- In 2012, he joined Orsingher Associate Lawyers.
- Professor at LUISS Guido Carli and Bocconi University, authored publications on IT law, and co-authored "Doing Business" for the World Bank.
- Committee and serving on the Board of ITechLaw.



Giuseppina Staropoli
Independent Director

- Over 20 years of experience in corporate legal consulting, gained in both national and international contexts.
- Founder of a law firm based in Rome and regular collaborator with other specialized law firms
- Advisor for investment funds, multinational groups, and SMEs on complex operations.
- Developed solid experience in designing and implementing organizational models pursuant to Legislative Decree 231/2001 and managing legal and regulatory risks.

EXECUTIVE LEADERSHIP



Neil Thomas
Chief Business Officer

- Partner in Ventac Partners since 2012 with executive roles in their portfolio companies.
- Previously Director of Business Development & IP at Genetrix, Madrid and Director IP & Technology at Roche spinout bioXell, Milan.
- Previously Adjunct Professor of IP in the Life Sciences Industry at IE Business School, Madrid and Visiting Lecturer at the University of Cambridge.



Chris Hentschel
Chief Scientific Officer

- Molecular biologist and Co-founder of The Ulysses Advisory Group.
- Held roles in MRC Technology Transfer UK, in the private sector (Celltech, UK; Centocor, USA).
- In public-private partnerships (MRC Collaborative Centre, UK; Medicines for Malaria Venture, Switzerland).
- Previously Partner and Chief Scientist at Bio Istanbul.



Natalie Pankova
Chief Operating Officer

- Doctor of Medicine (PhD) from the University of Toronto and a Masters from the Project Management Institute Global in Disciplined Agile Senior Scrum Master (DASSM).
- Her professional background gives her leadership in overseeing multiple functions including research and development.



Ennio Tasciotti
Scientific Director of
Technology Transfer

- Pioneer in biomimetic and regenerative medicine, with 25+ years of experience across research, clinical translation, and innovation.
- Ranked among the Top 1% of the most influential scientists worldwide by Stanford University.
- Founder and CSO of 3 biomedical startups, and Scientific Advisor to leading global healthcare companies.
- Former Chairman of the Department of Nanomedicine and Founder of 2 major research centers at Houston Methodist Hospital and Research Institute (USA).



Loris Spampinato
Chief Commercial Officer

- International executive with 30 years in the pharmaceutical and healthcare sectors, combining strategic vision with operational excellence.
- Former Chief Commercial and Business Development Officer at IBI Lorenzini and Mediolanum Farmaceutici.
- Held senior roles at MSD (Merck & Co.) in Europe and Canada, including Executive Director of Business Development and Strategic Alliances, and member of MSD's EURAM Leadership Team.



Alberto Carnesecca
Head of Sales

- Business Manager with 25 years of experience in Sales and Marketing in the healthcare sector.
- Held senior leadership roles across Business Development, Commercial, and Operations in Johnson & Johnson Medical and Medtronic Group,
- Spent the last 7 years as Business Manager with full P&L responsibility, leading a division focused on scouting, onboarding, and launching innovative technologies in Italy.

EXECUTIVE MANAGEMENT



Daria Brambilla
Scientific Head of
Venture Companies

- Consolidated experience in biochemistry, molecular biology, immunology and cell biology.
- Awarded a research grant at the Kimmel Cancer Center (PA, USA).
- PhD in Preclinical and Clinical Experimental Pharmacology.
- Grantee of a scholarship from Merck, Sharp & Dohme Research Institute IRBM P. Angeletti.



Giorgia Bellantonio
Head of People
and Culture

- Global HR leader with experience in driving sustainable business performance, creating exceptional workplace environments, inspiring employee experiences, and aligning a meaningful leadership culture with organizational strategy.
- Proven experience in driving business growth and performance, translating global organizational strategy while enabling performance-focused cultures.



Fabio Scognamiglio
Vice-President, Finance

- Temporary CFO since 2014 for various companies (including VC backed).
- Professor of Finance at John Cabot University and Lecturer at Luiss Business School.
- Former Finance Director at British American Tobacco.
- Former Strategy Consultant at Accenture.



Matteo Mazzoni
Head of Operations

- 15+ years of multi-industry experience including MedTech companies, in R&D and project management with leading firms like Flex, SAES Group, and Brembo.
- Master's degree in Mechanical Engineering with a specialization in Mechatronics from Politecnico di Milano.
- Proven expertise in technical innovation, project management, and strategic portfolio development. Inventor of 5 international patents.



Andrea Ingrosso
Business Developer

- PhD in Computer Science from the University of Milano-Bicocca.
- 15+ years of experience in project management, technology transfer, and startup consulting.
- Expert in leading projects focused on technological innovation, smart cities, and digital transformation.

STRATEGIC ADVISORY BOARD



Yossi Bornstein

- Over 35 years in Israeli & International biomed industry
- CEO and Founder of Shizim Group, ShizimXL (medical devices) and ShizimVS (digital health)
- Chairman of GCP Clinical Studies Ltd
- Founder of ILSI (Israel Life Science Industry Organization) and ITTN (Israel Tech Transfer Organization).
- External Director of Can-Fite BioPharma (NASDAQ: CANF)
- Former General Manager of Bristol-Myers Squibb (Israel).



Adam Broncel

- Co-founder and former GP, Biomed Venture Capital Fund
- Founder of Poland Ventures
- CEO Cogniguard
- Built an ecosystem for the growth and financing of foreign startups in Poland
- Transferred several Israeli startups to Poland
- Founder of several successful companies in across Western Europe
- Specializes in bringing international projects to Poland.



Slawomyr Chomik

- Over 20 years experience in the pharmaceutical industry in regional and global positions Former positions in global companies such as Solvay and Abbott
- Business Angel
- Lecturer, Faculty of Management, University of Warsaw
- Member, Polish Society of Cardiology
- Author of articles in the medical and economic press.



**Jeremy Curnok
Cook**

- Veteran in the life sciences/healthcare industry
- Founder and Managing Partner, BioScience Managers
- Decades of international experience in identifying investment opportunities, M&A and expansion into new geographies.
- Successfully managed in excess of US \$1 billion in equity investments
- Launched the first dedicated biotechnology fund for the Australian market
- Former Head, Life Science Private Equity team, Rothschild Asset Management
- Founder, International Biochemicals Group (sold to Royal Dutch Shell)
- Served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan, and Australia.



Yaron Itzhari

- Former CEO and Director, Medtronic, Israel
- Engineered the acquisition of startup companies, with a value of \$2B in Israel
- Led the integration of Covidien Israel into Medtronic Israel (the largest medical technology acquisition in the history of the industry)
- Founder and CEO and Chairman, Israeli MedTech Association
- Advisory Board Member, EyeControl
- Leading member of the top 25 High Tech leaders in Israel.



Adina Krausz

- CEO of InnoSource of Toledo Capital AG (consulting firm offering tailor- made services in the area of innovation and venture capital)
- Board Director, of Toledo Capital AG
- Over a decade of experience in portfolio management and wealth management
- Former Head of Investor Relationship and Business Development, BlueRock Group
- Former Head of Business Development, Private Banking Switzerland for First International Bank of Israel.

STRATEGIC ADVISORY BOARD



Pierre A. Morgon

- CEO of MRGN Advisors
- Regional Partner for Switzerland at Mérieux Equity Partners
- Senior Vice President, International Business at CanSino Biologics
- Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCBI and Health Technologies Holding
- Non-Executive Director to the Boards of Vaccitech, Univercells, Adiposs and Amoeba. Over 30 years of experience in the global life science industry
- Lecturer in several MBA programs and at the Mass Challenge incubator in Switzerland.



Mikael Oerum

- 40 years of experience in the pharmaceutical, biotech and finance sectors
- Raised over USD 300M in equity and soft funding into biotech companies
- Negotiated multi-millions in therapeutic, diagnostic and biochemical in- & out- licensing deals
- Orchestrated several IPOs and commercial product launches
- (Companies include Exiqon, RhoVac, Idogen and Coegin Pharma, and Cureon later renamed Santaris Pharma, which he spun out from Exiqon (sold to Hoffmann-La Roche).
- Founder of Ventac Partners
- Strategic Advisor to the Hong Kong Government for biotech industry development.



Fintan Walton

- CEO and Founder, PharmaVentures, a premier transaction advisory firm
- Co-founder, CONNECT Pharma
- His companies have delivered over 1,000 transaction-related assignments for companies in 38 countries. Clients include major pharma and biotech companies, diversified chemical corporations, medical device, generic, and OTC companies, investment banks, private equity and venture capital groups.
- Founder, PharmaDeals, the leading database and publishing business related to dealmaking data and analytics (sold to IMS Health, now IQVIA)
- Former management positions at Bass and Celltech plc (1982-1992).



Ferran Prat

- Over 30 years of experience in the Life Science industry in Diagnostics and Pharmaceuticals
- Former Corporate Vice President of Marketing, Strategic Alliances and Business Development, Chief Commercial Officer and Chief Operations Officer (companies include LETI Pharma and DAKO)
- Vice President, Werfen
- Board Member, AMADIX,
- Member, Ventac Partners
- President of the diagnostic sector at FENIN, the Spanish Federation of Health Technology Companies.



Wee Meng Thoo

- Head of Investments, Leonie Hill Capital, with presence in Singapore, New York and Switzerland focusing in disruptive businesses, STEM and Sustainability
- Co-investor with Family Offices and VC/PEs in startups from early to late stages and exits. Over 15 years of
- Operational Management Leadership roles in Global Tech firms (Hewlett Packard, Sun Microsystems/Oracle, VMware, Qatar Telecom/Oredoo)
- Former Chief Commercial Officer, NEC
- Board Director, SACA, a Swiss based Crypto Non-Profit Organization
- Board Advisor, 4IP.

A decorative background on the left side of the page consisting of a grid of teal-colored 3D cubes. The cubes are arranged in a staggered pattern, creating a textured, three-dimensional effect. The lighting is soft, casting subtle shadows between the cubes.

GET IN TOUCH!

Cube Labs S.p.A.
Via G. Caccini, 1
00198 – Rome, Italy
www.cube-labs.com
info@cube-labs.com